A pilot study of hippocampal volume and n-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD

European Neuropsychopharmacology

Volumn 23, Issue 4, 2013, Pages 276-284

  Abdallah, Chadi ^a   Coplan, Jeremy ^a   Jackowski, Andrea ^b   Sato, João ^b,c   Mao, Xiangling ^d   Shungu, Dikoma ^d   Mathew, Sanjay ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarkers; Disorder; Generalized anxiety; Glutamate; Hippocampal volume; Magnetic resonance spectroscopy; N acetylaspartate; Riluzole

Indexed keywords

N ACETYLASPARTIC ACID; PHARMACOLOGICAL BIOMARKER; RILUZOLE;

ADULT; ARTICLE; BRAIN LEVEL; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DELTA RHYTHM; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HIPPOCAMPUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PILOT STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84881543708     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.05.009     Document Type: Article

References (51)

1. Banasr, M., Chowdhury, G.M., Terwilliger, R., Newton, S.S., Duman, R.S., Behar, K.L., Sanacora, G., 2010. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry 15, 501-511.
2. Banasr, M., Duman, R.S., 2008. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol. Psychiatry 64, 863-870.
3. Brennan, B.P., Hudson, J.I., Jensen, J.E., McCarthy, J., Roberts, J.L., Prescot, A.P., Cohen, B.M., Pope Jr., H.G., Renshaw, P.F., Ongur, D., 2010. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsycho- pharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 35, 834-846.
4. Cavus, I., Pan, J.W., Hetherington, H.P., Abi-Saab, W., Zaveri, H.P., Vives, K.P., Krystal, J.H., Spencer, S.S., Spencer, D.D., 2008. Decreased hippocampal volume on MRI is associated with increased extracellular glutamate in epilepsy patients. Epilepsia 49, 1358-1366.
5. Duyn, J.H., Gillen, J., Sobering, G., van Zijl, P.C., Moonen, C.T., 1993. Multisection proton MR spectroscopic imaging of the brain. Radiology 188, 277-282.
6. First, M., Spitzer, R., Gibbon, M., Williams, J., 1995. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCIDI/P). Version 2.0. Biometric Research, New York State Psychiatric Institute, New York.
7. Fischl, B., Dale, A.M., 2000. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. USA 97, 11050-11055.
8. Frodl, T., Jager, M., Smajstrlova, I., Born, C., Bottlender, R., Palladino, T., Reiser, M., Moller, H.J., Meisenzahl, E.M., 2008. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J. Psychiatry Neurosci. 33, 423-430.
9. Frodl, T., Meisenzahl, E.M., Zetzsche, T., Hohne, T., Banac, S., Schorr, C., Jager, M., Leinsinger, G., Bottlender, R., Reiser, M., Moller, H.J., 2004. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J. Clin. Psychiatry 65, 492-499.
10. Fuchs, E., 2005. Social stress in tree shrews as ananimal model of depression: an example of a behavioral model of a CNS disorder. CNS Spectr. 10, 182-190.
11. Gourley, S.L., Espitia, J.W., Sanacora, G., Taylor, J.R., 2011. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology.
12. Halassa, M.M., Haydon, P.G., 2010. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 72, 335-355.
13. Hardingham, G.E., Bading, H., 2010. Synaptic versus extrasynaptic NMDA receptor signalling: implications forneurodegenerative disorders. Nat. Rev. Neurosci.11,682-696.
14. Hsieh, M.H., McQuoid, D.R., Levy, R.M., Payne, M.E., MacFall, J.R., Steffens, D.C., 2002.Hippocampal volume and antidepressant response ingeriatric depression. Int. J. Geriatr. Psychiatry 17, 519-525.
15. Katoh-Semba, R., Asano, T., Ueda, H., Morishita, R., Takeuchi, I.K., Inaguma, Y., Kato, K., 2002. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEBJ. Off. Publ. Fed. Am. Soc. Exp. Biol. 16, 1328-1330.
16. Kempton, M.J., Salvador, Z., Munafo, M.R., Geddes, J.R., Simmons, A., Frangou, S., Williams, S.C., 2011. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch. Gen. Psychiatry 68, 675-690.
17. Kondo, D.G., Hellem, T.L., Sung, Y.H., Kim, N., Jeong, E.K., Delmastro, K.K., Shi, X., Renshaw, P.F., 2011. Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res. Treat. 2011, 650450.
18. Kronmuller, K.T., Pantel, J., Kohler, S., Victor, D., Giesel, F., Magnotta, V.A., Mundt, C., Essig, M., Schroder, J., 2008. Hippocampal volume and 2-year outcome in depression. Br. J. Psychiatry J. Ment. Sci. 192, 472-473.
19. Krugers, H.J., Hoogenraad, C.C., Groc, L., 2010. Stress hormones and AMPA receptor trafficking in synaptic plasticity and memory. Nat. Rev. Neurosci. 11, 675-681.
20. Liu, A.Y., Mathur, R., Mei, N., Langhammer, C.G., Babiarz, B., Firestein, B.L., 2011a. Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J. Biol. Chem. 286, 2785-2794.
21. Liu, Q., Li, B., Zhu, H.Y., Wang, Y.Q., Yu, J., Wu, G.C., 2011b. Glia atrophy in the hippocampus of chronic unpredictable stressinduced depression model rats is reversed by electroacupuncture treatment. J. Affect. Disord. 128, 309-313.
22. MacQueen, G.M., Yucel, K., Taylor, V.H., Macdonald, K., Joffe, R., 2008. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol. Psychiatry 64, 880-883.
23. Mathew, S.J., Amiel, J.M., Coplan, J.D., Fitterling, H.A., Sackeim, H.A., Gorman, J.M., 2005. Open-label trial of riluzole in generalized anxiety disorder. Am. J. Psychiatry 162, 2379-2381.
24. Mathew, S.J., Hoffman, E., 2008. Pharmacotherapy for generalized anxiety disorder. Oxford Handb. Anxiety Relat. Disord., 350.
25. Mathew, S.J., Price, R.B., Mao, X., Smith, E.L., Coplan, J.D., Charney, D.S., Shungu, D.C., 2008. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol. Psychiatry 63, 891-898.
26. Mizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., Kuno, S., 2001. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett. 310, 117-120.
27. Moffett, J.R., Ross, B., Arun, P., Madhavarao, C.N., Namboodiri, A.M., 2007. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81, 89-131.
28. Murrough, J.W., Mao, X., Collins, K.A., Kelly, C., Andrade, G., Nestadt, P., Levine, S.M., Mathew, S.J., Shungu, D.C., 2010. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 23, 643-650.
29. Musazzi, L., Milanese, M., Farisello, P., Zappettini, S., Tardito, D., Barbiero, V.S., Bonifacino, T., Mallei, A., Baldelli, P., Racagni, G., Raiteri, M., Benfenati, F., Bonanno, G., Popoli, M., 2010. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 5, e8566.
30. Pankevich, D.E., Davis, M., Altevogt, B.M., 2011. Glutamate- Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary, Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary, Washington, DC.
31. Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J.H., Sanacora, G., 2008. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22, 761-786.
32. Radua, J., van den Heuvel, O.A., Surguladze, S., Mataix-Cols, D., 2010. Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders. Arch. Gen. Psychiatry 67, 701-711.
33. Rajkowska, G., Miguel-Hidalgo, J.J., 2007. Gliogenesis and glial pathology in depression. CNS Neurol. Disord. Drug Targets 6, 219-233.
34. Sanacora, G., Kendell, S.F., Levin, Y., Simen, A.A., Fenton, L.R., Coric, V., Krystal, J.H., 2007. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry 61, 822-825.
35. Sanacora, G., Treccani, G., Popoli, M., 2011. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology.
36. Sanacora, G., Zarate, C.A., Krystal, J.H., Manji, H.K., 2008. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 7, 426-437.
37. Schroeter, M.L., Abdul-Khaliq, H., Sacher, J., Steiner, J., Blasig, I.E., Mueller, K., 2010. Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc. Psychiatry Neurol. 2010, 780645.
38. Sexton, C.E., Mackay, C.E., Ebmeier, K.P., 2009. A systematic review of diffusion tensor imaging studies in affective disorders. Biol. Psychiatry 66, 814-823.
39. Soher, B.J., van Zijl, P.C., Duyn, J.H., Barker, P.B., 1996. Quantitative proton MR spectroscopic imaging of the human brain. Magn. Reson. Med. Off. J. Soc. Magn. Reson. Med./Soc. Magn. Reson. Med. 35, 356-363.
40. Spitzer, R., Williams, J., Gibbon, M., 1996. Structured Clinical Interview for DSM-IV: Non-patient Edition (SCID-NP). Biometrics Research Department, New York State Psychiatric Institute, New York.
41. Thomason, M.E., Thompson, P.M., 2011. Diffusion imaging, white matter, and psychopathology. Annu. Rev. Clin. Psychol. 7, 63-85.
42. Tsuchioka, M., Hisaoka, K., Yano, R., Shibasaki, C., Kajiatani, N., Takebayashi, M., 2011. Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells. Brain Res. 1384, 1-8.
43. Urenjak, J., Williams, S.R., Gadian, D.G., Noble, M., 1992. Specific expression of N-acetylaspartate in neurons, oligodendrocytetype-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 59, 55-61.
44. Vakili, K., Pillay, S.S., Lafer, B., Fava, M., Renshaw, P.F., Bonello-Cintron, C.M., Yurgelun-Todd, D.A., 2000. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol. Psychiatry 47, 1087-1090.
45. Valentine, G.W., Sanacora, G., 2009. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem. Pharmacol. 78, 431-439.
46. White, T., Nelson, M., Lim, K.O., 2008. Diffusion tensor imaging in psychiatric disorders. Top. Magn. Reson. Imaging 19, 97-109.
47. Yuen, E.Y., Liu, W., Karatsoreos, I.N., Ren, Y., Feng, J., McEwen, B.S., Yan, Z., 2011. Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. Mol. Psychiatry 16, 156-170.
48. Yuksel, C., Ongur, D., 2010. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry 68, 785-794.
49. Zarate Jr., C.A., Payne, J.L., Quiroz, J., Sporn, J., Denicoff, K.K., Luckenbaugh, D., Charney, D.S., Manji, H.K., 2004. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry 161, 171-174.
50. Zarate Jr., C.A., Quiroz, J.A., Singh, J.B., Denicoff, K.D., De Jesus, G., Luckenbaugh, D.A., Charney, D.S., Manji, H.K., 2005. An openlabel trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 57, 430-432.
51. Zink, M., Vollmayr, B., Gebicke-Haerter, P.J., Henn, F.A., 2010. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 58, 465-473.